Depakote is not exactly valproic acid, but it’s closely related. Depakote is the brand name for divalproex sodium, a compound made of sodium valproate and valproic acid bonded together in a 1:1 ratio. Once you swallow it, divalproex sodium breaks apart in your digestive tract and releases valproate, the same active ingredient found in pure valproic acid products. So while the pill itself is chemically distinct, the drug your body actually absorbs is the same.
How Depakote and Valproic Acid Differ
The distinction is mostly about packaging. Valproic acid was the original form, approved by the FDA in 1978 for seizures and sold under the brand name Depakene. It worked well but was known for causing significant stomach irritation. Divalproex sodium (Depakote) came along in 1986 as an enteric-coated alternative designed to be easier on the gut. By combining valproic acid with sodium valproate into a stable compound, the drug passes through the stomach before dissolving in the intestine, which reduces nausea and other GI side effects.
Once divalproex sodium reaches your intestine, it dissociates into the valproate ion, the same molecule your body would get from taking straight valproic acid. Blood tests don’t distinguish between the two: your doctor orders a “valproic acid level” regardless of which form you take.
Available Formulations
There are three main forms you might encounter:
- Depakene (valproic acid): the original capsule or liquid form
- Depakote (divalproex sodium delayed-release): enteric-coated tablets, typically taken two or three times daily
- Depakote ER (divalproex sodium extended-release): a once-daily tablet that releases the drug more slowly
These formulations are not perfectly interchangeable on a milligram-for-milligram basis. Depakote ER has about 89% of the bioavailability of standard Depakote when given at the same total daily dose. To compensate, doctors typically prescribe the extended-release version at a dose 8 to 20% higher than the delayed-release equivalent. The tablets themselves list their strength in terms of valproic acid equivalents, so a 500 mg Depakote ER tablet delivers the equivalent of 500 mg of valproic acid.
What Depakote Treats
Depakote is FDA-approved for three conditions. It treats manic episodes associated with bipolar disorder, making it one of the most commonly prescribed mood stabilizers. It’s approved for several types of epilepsy, including complex partial seizures (in adults and children age 10 and older) and absence seizures. It also prevents migraine headaches in adults, though it’s used for prevention rather than stopping a migraine already in progress.
The drug works primarily by increasing levels of a calming brain chemical called GABA and by blocking certain electrical signals in nerve cells. This dual action explains its usefulness across such different conditions: calming excessive electrical activity helps with seizures, while stabilizing nerve signaling helps regulate mood and reduce migraine frequency.
Common and Serious Side Effects
The most frequent side effects are nausea, drowsiness, dizziness, tremor, and weight gain. The enteric coating on Depakote reduces stomach problems compared to plain valproic acid, but GI symptoms can still occur, especially at higher doses.
Liver damage is one of the more serious risks, particularly in children under two and in people taking multiple seizure medications. Signs include unusual fatigue, facial swelling, loss of appetite, and vomiting. Routine blood work typically monitors liver function during the first several months of treatment.
Pancreatitis is a rarer but potentially life-threatening complication. In a systematic review of 125 reported cases, 84% of patients recovered, but 16% died from the pancreatic disease, on average seven days after diagnosis. Symptoms include sudden, severe pain in the upper abdomen along with nausea and vomiting. The condition typically appeared about 11 months after starting the medication, though it can occur at any point. Among patients who recovered and were put back on valproic acid, 84% developed pancreatitis again, which strongly suggests the drug was the direct cause.
Pregnancy Risks
All forms of valproate carry serious risks during pregnancy, and this applies equally to Depakote and Depakene since both deliver the same active drug. Children exposed to valproate before birth face a roughly 4.5-fold increased risk of intellectual disability and a 6-fold increased risk of delayed developmental milestones compared to unexposed children.
The risk appears to be dose-dependent. In one large study, children whose mothers took high doses (above 750 mg per day) had nearly 8 times the risk of intellectual disability. Children whose mothers took low doses (750 mg or less per day) showed no statistically significant increase in risk. These effects persisted even after researchers excluded children who were born with physical malformations, meaning the cognitive impact is independent of any visible birth defects.
Because of these risks, valproate in any form is generally considered a last resort for women of childbearing age, and pregnancy testing is typically required before starting treatment.